Reprocessing: the C2DS Pharmacist Club takes a stand
Authorizing reprocessing in France is a joint request from hospital federations (FHF, FHP, FEHAP), a repeated request from CLAPS, the central purchasing and referencing body for the healthcare sector, and a long-standing request from C2DS. The C2DS Pharmacy Club lobbied members of parliament.
When the cost of reprocessed DM is less than 50% of the cost of new DM, it's easy to see the financial benefits for facilities. Not to mention the savings on waste volumes. It's also in the patient's interest. When the time comes to choose between modern, costly techniques, opting for the best - which, when reprocessed, will be less costly - is beneficial in terms of quality of care. Reprocessing would also have a positive impact on employment: rather than shipping DM from the ends of the earth, a short reprocessing circuit would be set up. There are also environmental benefits: less transport and conservation of resources.
For devices eligible for this industrial process, quality requirements are now CE marked.